Opher Gileadi obtained his PhD in Biochemistry at the Hebrew University and was then a postdoctoral fellow at Stanford University Medical School. Subsequently he led a research group at the Weizmann Institute of Science. From 2004-2021 he was both at SGC University of Oxford, first as head of the Biotechnology group, then as Principal Investigator of the Genome Integrity & Repair Group as well as Head of the SGC Kinase Chemical Biology Center at the State University of Campinas (UNICAMP). In 2021 Opher took at position as Executive Director, Protein Science and Structure at Exscientia, but re-join the SGC at Karolinska in 2023.
Opher leads the Protein Science team at SGC Karolinska, focussing on developing antibodies and target-enabling packages (TEPs) for under-investigated proteins of humans and pathogens.
Matthieu Schapira, PhD is a Professor in the Department of Pharmacology and Toxicology, UofT, and is the head of computational chemistry, protein bioinformatics, and data management at the SGC-Toronto. He leads the CACHE initiative for benchmarking computational ‘hit finding’. Dr. Schapira is a recognized authority in the structural chemistry of drug target classes such as chromatin regulators, ubiquitylation pathways and WDR proteins, and has created popular online informatics resources for these targets such as Chromohub, Ubihub and ChemBioPort. He is interested in novel strategies to expand and ML tools to exploit the accessible chemistry space. His trainees have gone on to become important innovators in AI-driven drug discovery at Toronto-born biotechs such as Atomwise and Cyclica.
The mission of the Structural Genomics Consortium (“SGC”) Open Chemistry Networks platform (“Open Chem Networks”) is to bring together the knowledge, expertise, and resources of a large, distributed network of like-minded chemists from around the world to help SGC create new, open access Chemical Probes (defined below) against novel protein targets and to make them openly available to the research community without restrictions on use in order to catalyze research in new areas of human disease biology and drug discovery (the “
Who is involved in OCN?
This is an SGC initiative, and all SGC sites are contributing biochemistry and cell biology. There are synthetic chemistry contributors throughout the SGC, and the Head of Open Chemistry Networks is Professor Mat Todd at University College London.
What is open-source science?
SGC brings together a global network of organizations that support and collaborate on scientific research without retaining intellectual property rights or advanced knowledge of outputs. These include funding Members (Pfizer, Amgen, Novo Nordisk, AstraZeneca, Bristol Myers Squibb, Janssen) and Technology Partners (Nuvisan, Chemspace, Vernalis) who contribute expertise and capabilities across SGC research and affiliated initiatives.
Explore our official press releases to stay updated on our major accomplishments and new partnerships. Want to be the first to know about the latest news from SGC?
Read about the latest breakthroughs, awards and ongoing work from the SGC. Discover how our work is making a global impact and driving forward the field of drug discovery. Interested in getting first the latest news from SGC?
The Structural Genomics Consortium (SGC) is strongly committed to equity, diversity, and inclusion. We strive to create an environment that welcomes individuals from all groups, countries, organizations and institutions in our research community. With the mission of creating global access to drug discovery through open science, SGC also endeavours to further the diversity of ideas and approaches in the workplace.
In this unique project, pharmaceutical companies and leading academic laboratories make their innovative high-quality chemical probes available to the research community through the SGC. These donated probes complement the probes generated by the SGC and its collaborators. All compounds accepted into the donated probes program meet the chemical probe quality criteria and have been evaluated by an internal as well as an external expert committee. Moreover, several probes are suitable for in vivo use. Control compounds are also provided and profiled.
